About us
Team
Supervisory Board
Scientific Advisory Board
Clinical Advisors
Technology
Pipeline
Investors
Career
News & Events
Contact us
Menu
About us
Team
Supervisory Board
Scientific Advisory Board
Clinical Advisors
Technology
Pipeline
Investors
Career
News & Events
Contact us
About us
Team
Supervisory Board
Scientific Advisory Board
Clinical Advisors
Technology
Pipeline
Investors
Career
News & Events
Contact us
About us
Team
Supervisory Board
Scientific Advisory Board
Clinical Advisors
Technology
Pipeline
Investors
Career
News & Events
Contact us
Imprint
Privacy Statement
Disclaimer
Imprint
Privacy Statement
Disclaimer
News
Tubulis Announces Strategic License Agreement with Bristol Myers Squibb to Develop Next Generation ADCs for the Treatment of Cancer Patients
April 20, 2023
Article on Tubulis’ novel ADC conjugation technology P5 makes it to the cover of Chemical Science!
March 3, 2023
Tubulis Appoints Seasoned ADC Expert Björn Hock as Chief Development Officer
February 16, 2023
New Tubulis Paper in
Blood
highlights potential of next-generation ADC for effective & safe treatment of acute myeloid leukemia
September 13, 2022
ERP Article: Actualising the Power of Antibody-Drug Conjugates as Cancer Therapeutics
August 30, 2022
Tubulis moves into the Innovation and Startup Center for Biotechnology IZB in Martinsried
July 14, 2022
Tubulis Welcomes Mary Ann Lumiqued as Vice President Program Management
July 11, 2022
Tubulis Closes €60 Million Series B Financing to Accelerate its ADC Pipeline and Expand its Breadth of Platform Technologies
May 3, 2022
Olivier Marcq Joins Tubulis as Vice President CMC
April 5, 2022
Tubulis Publishes Deep-dive into Proprietary P5-Conjugation Technology in European Journal of Organic Chemistry
January 21, 2022
Tubulis Welcomes Magdalena Zikmundova as Associate Medical Director and Armin Weidmann as Vice President Quality
December 6, 2021
Tubulis Establishes Scientific Advisory Board with Leading ADC Drug Development and Oncology Experts
September 23, 2021
Tubulis Appoints Christian Grøndahl as Independent Chairman to Lead Supervisory Board
May 11, 2021
Tubulis appoints Günter Fingerle-Rowson as Chief Medical Officer to lead the clinical development of its new generation of ADCs
May 6, 2021
Tubulis Forms Strategic Partnership with WuXi Biologics and WuXi STA to Advance New Generation of Antibody-Drug Conjugates towards Clinical Evaluation
December 2, 2020
Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugates
July 21, 2020
Tubulis and Glycotope announce research and feasibility agreement for the discovery of antibody drug conjugates
September 11, 2019
Tubulis awarded at Venture.Med 2019
September 9, 2019